Log in

Entasis Therapeutics Stock Forecast, Price & News

-0.12 (-4.03 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $2.86
50-Day Range
MA: $2.81
52-Week Range
Now: $2.86
Volume206,007 shs
Average Volume97,749 shs
Market Capitalization$78.06 million
P/E RatioN/A
Dividend YieldN/A
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.27 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ETTX



Sales & Book Value

Annual Sales$7 million
Book Value$3.17 per share


Net Income$-43,850,000.00


Market Cap$78.06 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
-0.12 (-4.03 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

How has Entasis Therapeutics' stock been impacted by Coronavirus?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ETTX shares have decreased by 30.8% and is now trading at $2.86.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Entasis Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Entasis Therapeutics

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Entasis Therapeutics

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.06.
View Entasis Therapeutics' earnings history

What price target have analysts set for ETTX?

7 analysts have issued twelve-month target prices for Entasis Therapeutics' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate Entasis Therapeutics' stock price to reach $6.71 in the next year. This suggests a possible upside of 134.8% from the stock's current price.
View analysts' price targets for Entasis Therapeutics

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 59,600 shares, an increase of 358.5% from the August 15th total of 13,000 shares. Based on an average daily trading volume, of 221,700 shares, the days-to-cover ratio is currently 0.3 days. Approximately 36.1% of the shares of the company are sold short.
View Entasis Therapeutics' Short Interest

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Manoussos Perros, President, Chief Executive Officer & Director
  • Mike Gutch, Chief Financial Officer & Chief Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • Robin Isaacs, Chief Medical Officer
  • John Mueller, Chief Development Officer

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an initial public offering (IPO) on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

Who are Entasis Therapeutics' major shareholders?

Entasis Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Blackstone Group Inc (4.95%), Bridgeway Capital Management Inc. (0.26%), Janney Montgomery Scott LLC (0.38%) and Raymond James Financial Services Advisors Inc. (0.16%). Company insiders that own Entasis Therapeutics stock include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo, Innoviva, Inc and Nicholas Galakatos.
View institutional ownership trends for Entasis Therapeutics

Which major investors are selling Entasis Therapeutics stock?

ETTX stock was sold by a variety of institutional investors in the last quarter, including Blackstone Group Inc.
View insider buying and selling activity for Entasis Therapeutics

Which major investors are buying Entasis Therapeutics stock?

ETTX stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Janney Montgomery Scott LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Entasis Therapeutics stock in the last two years include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo, Innoviva, Inc, and Nicholas Galakatos.
View insider buying and selling activity for Entasis Therapeutics

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $2.86.

How big of a company is Entasis Therapeutics?

Entasis Therapeutics has a market capitalization of $78.06 million and generates $7 million in revenue each year. The company earns $-43,850,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is www.entasistx.com.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at 781-810-0120 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.